Chordia reported a change in its equity stake (from 17.49% to 16.40%), along with SBI Investment and others.

Filer: SBI Investment Co., Ltd. Date and Time of Filing: May 22, 2026, 16:21 Document Filed: Amendment Report (Cover Page = Amendment Report 11) Date Triggering Reporting Obligation: May 15, 2026 Reason for Filing Amendment Report: Decrease of 1% or more in shareholding ratio and decrease of 1% or more in standalone shareholding ratio Issuer: <190A> Chordia Therapeutics Shares

Jiji PressMay 22 03:24 ET

Chordia—Final results of the Phase I clinical trial in Japan for its CLK inhibitor have been published in a scientific journal.

On the 19th, Chordia Therapeutics <190A> announced that the final results paper from the first-in-human Phase I clinical trial in Japan of its CLK inhibitor "rogocekib (CTX-712)"—conducted in patients with advanced, recurrent, or refractory solid tumors—has been published in the journal Clinical Cancer Research. In this trial, 46 patients with solid tumors received twice-weekly dosing between 2018 and 2024.

Fisco JapanMay 20 21:13 ET

Express News | Kyoto University Innovation Capital has reported a reduction in its holding ratio of Chordia Therapeutics (190A.JP) shares to 4.68%.

Moomoo NewsMay 14 03:05 ET

Chordia—Acceptance of the 2026 EHA Rogocekib Dose-Escalation Cohort Abstract and Summary

Chordia Therapeutics <190A> announced on the 13th that a presentation on its lead pipeline CLK inhibitor rogocekib (CTX-712) has been accepted at the European Hematology Association (EHA) Annual Congress, and the presentation abstract has been published. The presentation covers data from the dose-escalation cohort in an ongoing Phase 1/2 clinical trial in the U.S. targeting patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes.

Fisco JapanMay 14 00:47 ET

Aftermarket [stocks that moved / stocks that traded]

Toray Industries, Inc. <3402>: Stock price at 1167.5 yen (+22 yen). Forecast for operating profit in the fiscal year ending March 2027 increased by 12.7%. Obayashi Corporation <1802>: Stock price at 3699 yen (-21 yen). Forecast for operating profit in the fiscal year ending March 2027 decreased by 7.5%. Bandai Namco Holdings <7832>: Stock price at 3817 yen (+168 yen). Operating profit for the fiscal year ending March 2026 increased by 5.2%, surpassing the previous forecast of a 0.4% increase. SANKYO Co., Ltd. <6417>: Stock price at 1732 yen (-83 yen). Operating profit decreased by 15.1% in the previous fiscal year and is forecast to decline by 10.4% this fiscal year. Zeon Corporation <4205>: Stock price at 2299.5 yen (+30 yen).

Fisco JapanMay 13 03:10 ET

Stocks that moved or traded actively in the morning session.

*PALTAC <8283> 6345 JPY - Continued convergence to the tender offer price implemented by Medipal HD. *Tokyo Enesis <1945> 2466 JPY +443 Significant increase in profits and dividend guidance viewed positively. *Nippon Kayaku <4272> 2139 JPY +358.5 Positive evaluation of consecutive profit forecasts and high-level share buybacks. *Nippon Business Systems <5036> 1630 JPY +258 Upward revision of earnings and dividend forecasts. *Oenon HD <2533> 501 JPY +79 Substantial growth in the first quarter.

Fisco JapanMay 13 00:58 ET